Data from four CRI-funded early-phase immunotherapy combination trials will be presented at the American Society for Clinical Oncology (ASCO) Annual meeting in Chicago in June.
Nonprofit Cancer Research Institute appoints pharmaceutical executive to lead its clinical research program
An innovative collaboration model designed to accelerate next-generation precision cancer immunotherapy through network of leading research centers and top scientists
CRI iAtlas to provide immune bioinformatics tool that aims to improve cancer immunotherapy research and drug effectiveness.
The two nonprofits partnered to support four scientists whose research is focused on developing immunotherapies for patients with fibrolamellar hepatocellular carcinoma.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
CRI scientists Dr. Michele Ardolino and Dr. David Raulet showed that Natural Killer cells can help eliminate tumors after checkpoint immunotherapy treatment even in the absence of T cells.
The third installment of the Rational Combinations 360 conference, which will be held in Philadelphia September 13-14, seeks to improve the design and application of combination immunotherapies for patients